About keros therapeutics inc - KROS
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
KROS At a Glance
Keros Therapeutics, Inc.
1050 Waltham Street
Lexington, Massachusetts 02421
| Phone | 1-617-314-6297 | Revenue | 244.06M | |
| Industry | Pharmaceuticals: Major | Net Income | 87.01M | |
| Sector | Health Technology | 2025 Sales Growth | 6,774.958% | |
| Fiscal Year-end | 12 / 2026 | Employees | 78 | |
| View SEC Filings |
KROS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 8.858 |
| Price to Sales Ratio | 3.158 |
| Price to Book Ratio | 1.313 |
| Price to Cash Flow Ratio | 7.17 |
| Enterprise Value to EBITDA | 6.936 |
| Enterprise Value to Sales | 2.05 |
| Total Debt to Enterprise Value | 0.034 |
KROS Efficiency
| Revenue/Employee | 3,128,987.179 |
| Income Per Employee | 1,115,564.103 |
| Receivables Turnover | 38.302 |
| Total Asset Turnover | 0.509 |
KROS Liquidity
| Current Ratio | 15.452 |
| Quick Ratio | 15.452 |
| Cash Ratio | 14.079 |
KROS Profitability
| Gross Margin | 99.382 |
| Operating Margin | 28.937 |
| Pretax Margin | 37.653 |
| Net Margin | 35.653 |
| Return on Assets | 18.151 |
| Return on Equity | 19.896 |
| Return on Total Capital | 27.191 |
| Return on Invested Capital | 19.207 |
KROS Capital Structure
| Total Debt to Total Equity | 5.57 |
| Total Debt to Total Capital | 5.276 |
| Total Debt to Total Assets | 4.924 |
| Long-Term Debt to Equity | 4.775 |
| Long-Term Debt to Total Capital | 4.523 |